Full text
Earnings transcript
Read the complete earnings call transcript.
MDXG
MiMedx Group, Inc.
$3.92
-0.03
(-0.76%)
| Exchange: | NASDAQ |
| Market Cap: | 582.381M |
| Shares Outstanding: | 5.677M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Joseph H. Capper | |||||
| Full Time Employees: | 837 | |||||
| Address: |
| |||||
| Website: | https://www.mimedx.com |
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company’s products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 321,477 | 348,879 | 418,630 |
| Gross Profit | 266,843 | 288,806 | 345,617 |
| EBITDA | 40,543 | 65,352 | 82,926 |
| Operating Income | 37,116 | 58,865 | 63,887 |
| Net Income | 67,439 | 42,419 | 48,578 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 239,047 | 263,915 | 342,653 |
| Total Liabilities | 96,330 | 70,808 | 86,105 |
| Total Stockholders Equity | 142,717 | 193,107 | 256,548 |
| Total Debt | 48,099 | 24,842 | 1,500 |
| Cash and Cash Equivalents | 82,000 | 104,416 | 166,121 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 26,775 | 66,198 | 74,003 |
| Capital Expenditure | -1,987 | -1,683 | 0 |
| Free Cash Flow | 24,788 | 64,515 | 74,003 |
| Net Income | 67,439 | 41,998 | 48,578 |
| Net Change in Cash | 16,050 | 22,416 | 61,705 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 445,935.082 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 581,856.096 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 517,799.999 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 41,367.807 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 53,976.714 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 48,034.459 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 53,992.154 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 76,473.289 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 65,878.783 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 317,379.496 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 414,116.768 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 368,526.966 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 0.440 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 0.510 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 0.360 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 1 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Revenue Growth: MiMedx reported a 13% revenue increase in Q2 2025, as highlighted in the earnings call transcript, reflecting strong demand for its product portfolio and effective market penetration within the healthcare sector.
- Solid Financial Position: Key metrics indicate a healthy current ratio (TTM) and quick ratio (TTM), suggesting strong liquidity to meet short-term obligations. Additionally, positive free cash flow (TTM) supports operational stability and potential reinvestment.
- Strong Product Portfolio: The earnings call emphasized MiMedx's ability to leverage its product offerings, positioning the company as a leader in its niche within the biotechnology industry, as supported by revenue product segment data.
- Market Presence and Adaptability: The earnings call transcript notes MiMedx's capability to adapt to evolving reimbursement landscapes, underpinned by a strong market presence, which enhances its competitive edge.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates MDXG intrinsic value between $6.10 – $6.37 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about MDXG valuation
Is MiMedx Group, Inc. (MDXG) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for MiMedx Group, Inc. (MDXG) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is MDXG a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether MDXG trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is MDXG’s P/E ratio?
You can see MDXG’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for MDXG?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is MDXG a good long-term investment?
Whether MDXG fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
MDXG
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.76
Trading Metrics:
| Open: | 3.89 | Previous Close: | 3.95 | |
| Day Low: | 3.81 | Day High: | 3.94 | |
| Year Low: | 3.77 | Year High: | 7.99 | |
| Price Avg 50: | 4.75 | Price Avg 200: | 6.31 | |
| Volume: | 1.67M | Average Volume: | 1.173M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeMDXG full analysis
Welcome to MARKETSNAP’s SWOT analysis for MiMedx Group, a player in the biotech space that might not be on everyone’s radar just yet. If you’re a long-term investor looking to uncover potential gems in the healthcare sector, stick with me as we dive into what makes MiMedx tick, break down their strengths, weaknesses, opportunities, and threats, and figure out if this stock deserves a spot in your portfolio. First, let’s get a quick lay of the land. MiMedx Group operates…
